Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 5, 2009 - Issue
Submit an article Journal homepage
79
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Biphosphonates-related osteonecrosis of the jaw: Clinical and physiopathological considerations

Alberto Borgioli1 Department of Odontostomatology, Dental School
,
Christian Viviani1 Department of Odontostomatology, Dental School
,
Marco Duvina1 Department of Odontostomatology, Dental School
,
Leila Brancato1 Department of Odontostomatology, Dental School
,
Giuseppe Spinelli1 Department of Odontostomatology, Dental School
,
Maria Luisa Brandi2 Department of Internal Medicine;3 DeGene Spin-off, Medical School, University of Florence, Florence, ItalyCorrespondence[email protected]
&
Paolo Tonelli1 Department of Odontostomatology, Dental School
 show all
Pages 217-227 | Published online: 27 Feb 2009

Figures & data

Figure 1 Osteolytic lesion in the lower jaw of patient treated with Zometa® for 12 months (59 years old, female, breast cancer).
Figure 1 Osteolytic lesion in the lower jaw of patient treated with Zometa® for 12 months (59 years old, female, breast cancer).
Figure 2 Worsening of the lesion after sequestrectomy in patient treated with Zometa® for 12 months (59 years old, female, breast cancer).
Figure 2 Worsening of the lesion after sequestrectomy in patient treated with Zometa® for 12 months (59 years old, female, breast cancer).
Figure 3 Cutaneous fistula in patient treated with Aredia® and Zometa® for 24 months (48 years old, female, breast cancer).
Figure 3 Cutaneous fistula in patient treated with Aredia® and Zometa® for 24 months (48 years old, female, breast cancer).
Figure 4 Computed tomographic scan of the bone sequestrum in patient treated with Zometa® for 5 months (75 years old, female, breast cancer).
Figure 4 Computed tomographic scan of the bone sequestrum in patient treated with Zometa® for 5 months (75 years old, female, breast cancer).
Figure 5 Spontaneous fracture of the lower jaw in patient treated with Aredia® and Zometa® for 24 months (43 years old, female, breast cancer).
Figure 5 Spontaneous fracture of the lower jaw in patient treated with Aredia® and Zometa® for 24 months (43 years old, female, breast cancer).
Figure 6 Early clinical picture of the lower jaw in patient treated with Aredia® and Zometa® for 24 months (48 years old, female, breast cancer).
Figure 6 Early clinical picture of the lower jaw in patient treated with Aredia® and Zometa® for 24 months (48 years old, female, breast cancer).
Figure 7 Advanced lesion of the upper jaw in patient treated with Zometa® for 12 months (69 years old, male, multiple myeloma).
Figure 7 Advanced lesion of the upper jaw in patient treated with Zometa® for 12 months (69 years old, male, multiple myeloma).
Figure 8 Abscessual complication of necrotic bone lesion in patient treated with Zometa® for 11 months (61 years old, male, prostatic cancer).
Figure 8 Abscessual complication of necrotic bone lesion in patient treated with Zometa® for 11 months (61 years old, male, prostatic cancer).

Table 1 Treatment of patients with osteonecrosis of the jaw

Figure 9 Use of platelet-rich plasma in the surgical treatment of the lesion in patient treated with Zometa® for 12 months (59 years old, female, breast cancer).
Figure 9 Use of platelet-rich plasma in the surgical treatment of the lesion in patient treated with Zometa® for 12 months (59 years old, female, breast cancer).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.